The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
According to the estimates by IMARC Group, the global biopharmaceutical third-party logistics (3PL) market is expected to witness a CAGR of 7% during 2021-2026.
The increasing adoption of outsourced logistics services by various medical organizations to optimize their distribution network represents one of the key drivers for the global biopharmaceutical third-party logistics (3PL) market.
The rising integration of 3PL services with warehouse robotics, mobile cloud computing, real-time monitoring, and data mining solutions, represents one of the key trends in the global biopharmaceutical third-party logistics (3PL) market.
Sudden outbreak of the COVID-19 pandemic had led to a significant increase in the demand for 3PL logistics to minimize drug supply disruptions and prioritize the availability of critical care drugs.
On the basis of the supply chain, the market has been divided into cold chain and non-cold chain. Among these, non-cold chain represents the largest segment.
On the basis of the service type, the market has been bifurcated into transportation, warehousing and storage, and others. Currently, warehousing and storage holds the majority of the total market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global biopharmaceutical third-party logistics (3PL) market are Agility Logistics, AmerisourceBergen Corporation, DB Schenker (Deutsche Bahn), DHL International GmbH (Deutsche Post), FedEx Corporation, Kerry Logistics Network Limited, Kuehne + Nagel International AG, McKesson Corporation, SF Express Co. Ltd., and United Parcel Service of America Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at